Please login to the form below

Not currently logged in
Email:
Password:

NICE backs Amicus Therapeutics’ Galafold

Recommends oral alternative for treating Fabry disease
NICE

The UK's NICE has recommended the use of Galafold (migalastat) on the NHS for the treatment of Fabry disease in draft Highly Specialised Technologies guidance.

The committee gave Amicus Therapeutics' genetic disorder treatment the provisional green light, bringing UK patients one step closer to an orally administered alternative to the standard fortnightly injections.

Despite initial uncertainty over its clinical effectiveness, the cost-effectiveness watchdog concluded that Galafold provides enough similar benefits to current enzyme replacement therapies (ERT), such as Sanofi's Fabrazyme (agalsidase beta) and Shire's Replagal (agalsidase alfa).

The regulator has agreed a confidential discount for the therapy with Amicus, creating a patient access scheme to reduce pricing from its annual treatment cost of £210,000 per patient in line with current ERT programmes.

Fabry disease affects an estimated 855 people in England, of whom around 140 would be eligible for treatment with Galafold.

An incurable inherited genetic disorder, Fabry disease is caused by a faulty enzyme responsible for breaking down fatty substances in the body's cells. Build up of lipids in blood vessel walls decreases blood flow to tissues and so often results in irreversible organ damage, progressive kidney and heart disease and increased risk of stroke.

Article by
Rebecca Clifford

28th October 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...
APAC map
Pharmaceutical innovation in the APAC region
A first-of-its-kind study paints a vivid picture of the APAC region’s future...

Infographics